[Click eStock] "NKMax. Focus on Giant Growth Momentum"

On the 28th, KB Securities analyzed that NKMAX should be noted for its giant growth momentum. They did not provide an investment opinion or target price.

KB Securities explained that clinical announcements related to solid tumors (sarcoma) in the second half of the year should be closely watched. Clinical Researcher Im Kook at KB Securities stated, "The final results of the US Phase 1 clinical trial related to refractory sarcoma are expected to be announced in the second half of the year," adding, "Following the interim data, expectations are rising for positive data in the final results, opening possibilities for future Phase 2 clinical trials, technology exports, and commercialization."

Additionally, a revaluation of corporate value is also expected. He said, "The US subsidiary NKGen Biotech is scheduled to be listed on NASDAQ through a merger with the SPAC 'Graf'," and added, "After listing, NKGen Biotech is expected to not only compete with global NK cell therapy companies but also accelerate clinical momentum through fundraising and planned clinical progress, leading to a revaluation of corporate value."

He also emphasized that collaboration with China's Sugang Group is another aspect to watch. He stated, "NKMAX plans to expand its product supply lineup beyond the initial supply of the immune-enhancing health functional food ‘NK365’ through collaboration with Sugang Group," and emphasized, "If the main contract is finalized, including an investment attraction of approximately 50 million USD from Sugang Group, significant synergy effects are expected, such as improved financial structure and accelerated development of clinical pipelines."

This content was produced with the assistance of AI translation services.